| abstract |
REFERS TO PIPERIDINE-SUBSTITUTED COMPOUNDS OF FORMULA (I) WHERE X1 IS CH2 AND X2 IS NR2 OR X1 IS NR2 AND X2 IS CH2; R1 IS H, (C1-C4) ALKYL, HALOGEN OR CN; R2 IS H, ALKYL (C1-C8) OR HALOALKYL (C1-C8); R3 IS ALKYL (C1-C8), OR R2 AND AN ADJACENT R3, OR R3 AND AN ADJACENT R3, TOGETHER WITH THE ATOMS OF THE RING TO WHICH THEY ARE ATTACHED, FORM A FUSED CYCLOALKYL OR HETEROCICLE RING OF FIVE OR SIX MEMBERS; n IS FROM 0 TO 4. THE PREFERRED COMPOUNDS ARE: (R) -6 - ((6-AMINO-5-METHYLPYRIMIDIN-4-IL) AMINO) -1 ', 8-DIMETHYL-2H-SPIRO [IMIDAZO [1,5 -a] PYRIDINE-3,3'-PIPERIDINE] -1,5-DIONA; (R) -4-AMINO-6 - ((1 ', 8-DIMETHYL-1,5-DIOXO-1,5-DIHYDRO-2H-SPYRO [IMIDAZO [1,5-a] PYRIDINE-3,3'- PIPERIDIN] -6-IL) AMINO) PYRIMIDINE-5-CARBONITRILE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE KINASE INHIBITORS THAT INTERACT WITH MAP KINASE (MnK), BEING USEFUL IN THE TREATMENT OF CANCER |